Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739457 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL15744027 | 0.93 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL3469807 | 0.91 | HTT (0.43) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL1766175 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL31377991 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL24743370 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL512256 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL29804996 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL11251378 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL2955974 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2133332-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1960389-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885KDM4E 3666/4885CYP3A4 684/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885KDM4E 3666/4885CYP3A4 684/4885 |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | ALDH1A1 424/4885KDM4E 399/4885CYP3A4 1038/4885 |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | ALDH1A1 1574/4885KDM4E 4368/4885CYP3A4 533/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1370/4885KDM4E 3578/4885CYP3A4 715/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885KDM4E 3666/4885CYP3A4 684/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | ALDH1A1 4276/4885KDM4E 2050/4885CYP3A4 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.